NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$140.38 +0.73 (+0.52 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$139.65
Today's Range$139.05 - $143.96
52-Week Range$130.15 - $184.00
Volume825,500 shs
Average Volume529,084 shs
Market Capitalization$8.52 billion
P/E Ratio14.68
Dividend YieldN/A
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:JAZZ
Previous Symbol


Debt-to-Equity Ratio0.52
Current Ratio4.29
Quick Ratio4.16


Trailing P/E Ratio14.68
Forward P/E Ratio12.10
P/E Growth0.85

Sales & Book Value

Annual Sales$1.62 billion
Price / Sales5.23
Cash Flow$12.9502 per share
Price / Cash Flow10.84
Book Value$45.26 per share
Price / Book3.10


EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Net Margins28.09%
Return on Equity24.92%
Return on Assets13.36%


Outstanding Shares60,320,000
Market Cap$8.52 billion

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its earnings results on Tuesday, November, 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, topping analysts' consensus estimates of $3.32 by $0.26. The specialty pharmaceutical company had revenue of $469.37 million for the quarter, compared to the consensus estimate of $482.64 million. Jazz Pharmaceuticals had a return on equity of 24.92% and a net margin of 28.09%. The firm's revenue for the quarter was up 14.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.22 earnings per share. View Jazz Pharmaceuticals' Earnings History.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Jazz Pharmaceuticals.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share (EPS) guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus estimate of $13.11. The company issued revenue guidance of $1.86-1.90 billion, compared to the consensus revenue estimate of $1.92 billion.Jazz Pharmaceuticals also updated its FY 2018 guidance to $12.75-13.25 EPS.

What price target have analysts set for JAZZ?

18 Wall Street analysts have issued 12-month price objectives for Jazz Pharmaceuticals' stock. Their predictions range from $157.00 to $210.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $189.2353 in the next twelve months. This suggests a possible upside of 34.8% from the stock's current price. View Analyst Price Targets for Jazz Pharmaceuticals.

What is the consensus analysts' recommendation for Jazz Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "After lower-than-expected sales in 2017, Jazz’ sleep disorder drug, Xyrem witnessed improved volume trends in the first half. Management seems confident that Xyrem will continue to generate volume growth in 2018 and beyond. Jazz’s lead pipeline candidate JZP-110 complements its existing sleep disorder portfolio. Jazz is also actively evaluating business development deals to enhance its product line and pipeline. Shares of the company have outperformed the industry so far this year. However, Jazz has been facing supply constraints for its leukemia drug, Erwinaze, due to constrained manufacturing capacity. These supply challenges are expected to continue in 2018. Meanwhile, its newest drug Vyxeos performed below expectations and Jazz lowered its full-year outlook. Earnings estimates have gone down ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (11/13/2018)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and we are lowering our PT by $2 to $201 for JAZZ stock. We continue to believe management has positioned the company well for a solid financial performance in a post-Xyrem" world through innovation and diversification. We believe NT stock performance will be driven by potential FDA approval of solriamfetol and JZP-258 data in narcolepsy." (11/6/2018)
  • 3. HC Wainwright analysts commented, "We highlighted after 1Q that management seemed to be taking a decidedly conservative approach to guidance this year, and this quarter we again see a healthy beat with little or no full-year raise. We still think guidance is a bit conservative (we’re near the high end on REV and EPS), but besides a small revenue drag from the sale of Prialt, unfortunately there was a key underperformer holding Jazz guidance back: Vyxeos. Jazz’s newest growth driver, from its most recent acquisition, only grew modestly QoQ, missed consensus for the second straight quarter, and Jazz lowered the product’s 2018 guidance 12% at the midpoint to $115-135M." (8/9/2018)
  • 4. Mizuho analysts commented, "We reiterate our Neutral rating and $150 PT post-1Q:18 beat & improved guidance. We think investors may now be concerned about deal risk in the name." (5/9/2018)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

Press coverage about JAZZ stock has been trending somewhat positive on Tuesday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Jazz Pharmaceuticals earned a news impact score of 1.1 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Jazz Pharmaceuticals' key competitors?

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the folowing people:
  • Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
  • Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)
  • Ms. Karen J. Wilson, Sr. VP of Fin. & Principal Accounting Officer (Age 55)

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (9.52%), Vanguard Group Inc. (8.10%), BlackRock Inc. (7.43%), Putnam Investments LLC (7.16%), JPMorgan Chase & Co. (3.17%) and Bank of New York Mellon Corp (2.80%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.

Which institutional investors are selling Jazz Pharmaceuticals stock?

JAZZ stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Putnam Investments LLC, Partner Fund Management L.P., Epoch Investment Partners Inc., Allianz Asset Management GmbH, Schroder Investment Management Group, Mitsubishi UFJ Trust & Banking Corp and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul Treacy and Rick E Winningham. View Insider Buying and Selling for Jazz Pharmaceuticals.

Which institutional investors are buying Jazz Pharmaceuticals stock?

JAZZ stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Bank of New York Mellon Corp, Victory Capital Management Inc., Martingale Asset Management L P, Acadian Asset Management LLC, BlackRock Inc., First Trust Advisors LP and American Century Companies Inc.. View Insider Buying and Selling for Jazz Pharmaceuticals.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $140.38.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $8.52 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.

What is Jazz Pharmaceuticals' official website?

The official website for Jazz Pharmaceuticals is

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]

MarketBeat Community Rating for Jazz Pharmaceuticals (NASDAQ JAZZ)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  836 (Vote Outperform)
Underperform Votes:  317 (Vote Underperform)
Total Votes:  1,153
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel